

ASTRAZENECA PLC
Form 6-K
February 04, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of February 2015

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

AstraZeneca Fourth Quarter and Full Year Results 2014

On Thursday, 5 February 2015, AstraZeneca will release fourth quarter and full year results for 2014 at 07:00GMT.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

An analyst presentation covering the results will be held at 12:00gmt and can be joined, live, via teleconference on the following numbers:

UK (freephone): 0800 694 2370
US (freephone): 1 866 977 7645
Swedish (freephone): 0200 883 079
International: +44 (0)1452 557 749

Conference ID: 75172849 *you will be asked for the Conference ID when you join the call*

Printable pdf versions of slides will be available to download on the AstraZeneca Investor Relations website <http://www.astrazeneca.com/investors> and the AstraZeneca Events website: <http://info.astrazenecaevents.com> 15 minutes before the analyst presentation begins.

Details of the teleconference and webcast replay facilities are available on the Investor Relations section of the AstraZeneca Investor Relations website www.astrazeneca.com/investors and the AstraZeneca Events website: <http://info.astrazenecaevents.com>.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 04 February 2015

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary